ascendis transcon glp-1 program

ascendis transcon glp-1 program Novo inks deal to develop long-acting GLP-1, other metabolic drugs Novo Nordisk signs $285m deal – Ascendis Pharma submits MAA for

Name: ascendis transcon glp-1 program Novo inks deal to develop long-acting GLP-1, other metabolic drugs Novo Nordisk signs $285m deal – Ascendis Pharma submits MAA for
Brand: kawsara-prestige.com
SKU: 63016220037
Price: 23.99 USD
Availability: InStock
Rating: 4.5436000000000005 (20 reviews)

SKU: 63016220037

4.5

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 10 - Aug 15

Description

Discovery and history Discovered in 1973 by Dr

In a recent 12-week, randomized, placebo-controlled trial in untreated hypertensive subjects, daily intake of aged garlic extract (1.2 g of which contained 1.2 mg of S-allyl-L-cysteine [SAC]) was shown to significantly lower SBP by 11 mm Hg and DBP by 6 mm Hg on average in 50%-60% of participants, but reductions in blood pressure were not reported in 40%-50% of participants compared to placebo (110)

Semaglutide was the first GLP-1RA to meet the primary endpoint in a phase II NASH trial